Overview
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
Status:
Completed
Completed
Trial end date:
2005-06-01
2005-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the parent study 137-150.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZenecaTreatments:
Islet Amyloid Polypeptide
Pramlintide
Criteria
Inclusion Criteria:- The subject has completed the full dosing period in Protocol 137-150.